CMS: Data shows moderate support for Provenge use

All of the available data for Dendreon's Provenge prostate cancer vaccine shows 'moderate' support for its use, according to a government analysis. CMS, which meets with outside advisers next Wednesday to discuss paying for the vaccine, analyzed all the available evidence for the therapy that has had drawn scrutiny for its large price tag amid praise from cancer advocates. Company shares, which closed at $34.83, rose 5.4 percent to $36.70 in after-hours trading. Also, Dendreon says it has applied for FDA approval to essentially quadruple the capacity of its New Jersey factory. Story | News